ConductScience.org, home

Paper32434945

DNA vaccine protection against SARS-CoV-2 in rhesus macaques.

Yu J and 53 others. Science, 2020. Cited by 864 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Papers, record 32434945. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32434945

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
PubMed
Journal
Science
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
864
iCite
Relative citation ratio, by iCite
35.6
iCite
Revised in PubMed
2026-04-22
PubMed

Authors54

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

See all 54 authors

Topics30

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BetacoronavirusMajor topic
Coronavirus InfectionsMajor topic
PandemicsMajor topic
Pneumonia, ViralMajor topic
Spike Glycoprotein, CoronavirusMajor topic
Vaccines, DNAMajor topic
Viral VaccinesMajor topic
Adjuvants, Immunologic
Animals
Antibodies, Neutralizing
Antibodies, Viral
Bronchoalveolar Lavage Fluid
COVID-19
COVID-19 Vaccines
Disease Models, Animal
Female
Humans
Immunity, Cellular
Immunity, Humoral
Immunization, Secondary
Immunogenicity, Vaccine
Immunologic Memory
Macaca mulatta
Male
Mutant Proteins
Nasal Mucosa
Protein Domains
SARS-CoV-2
Vaccination
Viral Load

Source PubMed

Grants16

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
T32 AI007387NIAID NIH HHSUnited StatesT32AI007387PubMed and NIHNIH RePORTER
R01 AI110700NIAID NIH HHSUnited StatesR01AI110700PubMed and NIHNIH RePORTER
T32 AI007151NIAID NIH HHSUnited StatesT32AI007151PubMed and NIHNIH RePORTER
R01 AI139538NIAID NIH HHSUnited StatesR01AI139538PubMed and NIHNIH RePORTER
R01 AI108197NIAID NIH HHSUnited StatesR01AI108197PubMed and NIHNIH RePORTER
UM1 AI126603NIAID NIH HHSUnited StatesUM1AI126603PubMed and NIHNIH RePORTER
R01 AI147884NIAID NIH HHSUnited StatesR01AI147884PubMedNIH RePORTER
R01 AI146779NIAID NIH HHSUnited StatesR01AI146779PubMed and NIHNIH RePORTER
R01 AI121394NIAID NIH HHSUnited StatesR01AI121394PubMed and NIHNIH RePORTER
U01 AI149644NIAID NIH HHSUnited StatesU01AI149644PubMed and NIHNIH RePORTER
R01 OD024917NIH HHSUnited StatesR01OD024917PubMed and NIHNIH RePORTER
UM1 AI124377NIAID NIH HHSUnited StatesUM1AI124377PubMed and NIHNIH RePORTER
U19 AI100625NIAID NIH HHSUnited StatesU19AI100625PubMed and NIHNIH RePORTER
R01 AI129797NIAID NIH HHSUnited StatesR01AI129797PubMed and NIHNIH RePORTER
R01 AI132178NIAID NIH HHSUnited StatesR01AI132178PubMed and NIHNIH RePORTER
U19 AI128751NIAID NIH HHSUnited StatesU19AI128751PubMed and NIHNIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04944095Change in Antibody Levels Following SARS-CoV-2 (Covid-19) VaccinationsBackground

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131,995,857Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.N Engl J Med2020https://conductscience.org/library/papers/31995857PubMed
231,978,945A Novel Coronavirus from Patients with Pneumonia in China, 2019.N Engl J Med2020https://conductscience.org/library/papers/31978945PubMed
314,569,023Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus.Proc Natl Acad Sci U S A2003https://conductscience.org/library/papers/14569023PubMed
429,246,504A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization.Antiviral Res2018https://conductscience.org/library/papers/29246504PubMed
532,385,100Rapid COVID-19 vaccine development.Science2020https://conductscience.org/library/papers/32385100PubMed
615,024,391A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.Nature2004https://conductscience.org/library/papers/15024391PubMed
732,007,143Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet2020https://conductscience.org/library/papers/32007143PubMed
829,237,759Durability and correlates of vaccine protection against Zika virus in rhesus monkeys.Sci Transl Med2017https://conductscience.org/library/papers/29237759PubMed
926,544,943Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.Cell2015https://conductscience.org/library/papers/26544943PubMed
1018,824,060A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.Vaccine2008https://conductscience.org/library/papers/18824060PubMed
1132,015,508A new coronavirus associated with human respiratory disease in China.Nature2020https://conductscience.org/library/papers/32015508PubMed
1231,986,261A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.Lancet2020https://conductscience.org/library/papers/31986261PubMed
1332,015,507A pneumonia outbreak associated with a new coronavirus of probable bat origin.Nature2020https://conductscience.org/library/papers/32015507PubMed
1432,075,877Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.Science2020https://conductscience.org/library/papers/32075877PubMed
1528,807,998Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.Proc Natl Acad Sci U S A2017https://conductscience.org/library/papers/28807998PubMed
1617,559,989Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques.Vaccine2007https://conductscience.org/library/papers/17559989PubMed
1732,376,603Development of an inactivated vaccine candidate for SARS-CoV-2.Science2020https://conductscience.org/library/papers/32376603PubMed
1815,837,221Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.Vaccine2005https://conductscience.org/library/papers/15837221PubMed
1930,830,861Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.JCI Insight2019https://conductscience.org/library/papers/30830861PubMed
2032,235,945Virological assessment of hospitalized patients with COVID-2019.Nature2020https://conductscience.org/library/papers/32235945PubMed

See all 29 references

Cited by663

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 864 citations.

PMIDTitleJournalYearIn PapersSource
42,903,854Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms.Hlife2024https://conductscience.org/library/papers/42903854PubMed
42,842,678Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus.Sci Adv2026https://conductscience.org/library/papers/42842678PubMed
42,307,560The Association of Primate Veterinarians and the European Primate Veterinarians Position Statement on the Value of Nonhuman Primates in Research.J Am Assoc Lab Anim Sci2026https://conductscience.org/library/papers/42307560PubMed
42,288,524Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2.Sci Rep2026https://conductscience.org/library/papers/42288524PubMed
42,118,760Trends of laboratory nonhuman primate licensing in China between 2020 and 2024: A national database analysis.PLoS One2026https://conductscience.org/library/papers/42118760PubMed
42,063,787
A phase 1, single-center, randomized, dose finding study to evaluate the safety, tolerability, and immunogenicity of a prophylactic COVID-19 pDNA vaccine after single ascending doses in healthy adults.
Front Med (Lausanne)2026https://conductscience.org/library/papers/42063787PubMed
42,000,737Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine.NPJ Vaccines2026https://conductscience.org/library/papers/42000737PubMed
41,867,858Exposure route drives SARS-CoV-2 infection patterns in non-human primates.bioRxiv2026https://conductscience.org/library/papers/41867858PubMed
41,862,531Vaccine-derived T-cell responses are insufficient to generate protective immunity to SARS-CoV-2.Sci Rep2026https://conductscience.org/library/papers/41862531PubMed
41,839,978Evaluating southern pigtail macaques as an immunological model for human antibody responses.Sci Rep2026https://conductscience.org/library/papers/41839978PubMed
41,441,723Immunogenicity of Sulfated Lactosyl Archaeol Archaeosome-Adjuvanted Versus Non-Adjuvanted SARS-CoV-2 Spike Booster Vaccines in Young and Aged Balb/c Mice.Vaccines (Basel)2025https://conductscience.org/library/papers/41441723PubMed
41,383,761Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like Betacoronaviruses.bioRxiv2025https://conductscience.org/library/papers/41383761PubMed
41,295,541Current Status and Challenges of Vaccine Development for Seasonal Human Coronaviruses.Vaccines (Basel)2025https://conductscience.org/library/papers/41295541PubMed
41,136,184Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort.Gut2026https://conductscience.org/library/papers/41136184PubMed
40,957,415Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines.Cell2025https://conductscience.org/library/papers/40957415PubMed
40,841,372Highly scalable prefusion-stabilized RSV F vaccine with enhanced immunogenicity and robust protection.Nat Commun2025https://conductscience.org/library/papers/40841372PubMed
40,740,485SARS-CoV-2 vaccines elicit differential Fc effector functions.iScience2025https://conductscience.org/library/papers/40740485PubMed
40,561,578When less is statistically Equivalent: Lobe-Specific optimization of histopathological assessment in SARS-CoV-2 pneumonia.Comput Biol Med2025https://conductscience.org/library/papers/40561578PubMed
40,477,216SARS-CoV-2 virus: Vaccines in development.Fundam Res2021https://conductscience.org/library/papers/40477216PubMed
40,477,151Current progress and challenges in the design and development of a successful COVID-19 vaccine.Fundam Res2021https://conductscience.org/library/papers/40477151PubMed

See all 663 cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32434945

GET https://conductscience.org/api/papers/v1/32434945/authors?page=2